Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a class of antihyperglycemic drugs that were first approved for treatment of patients with T2DM in 2005 [14]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.